Green Light for Malaria Vaccine
After 28 years of R&D at GSK, the world has its first malaria vaccine
Stephanie Sutton |
In July, GlaxoSmithKline’s Mosquirix received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Health. The positive news – and world first – follows nearly 30 years of research and development; the candidate was proposed by GSK scientists in 1987.
The vaccine will be used in sub-Saharan Africa and is cleared for use in children aged 6 weeks to 17 months, with clinical trials showing that it should help offer protection from malaria for at least three years (1). The Phase III trial involved more than 16,000 young children and was conducted by 13 research centers in eight African countries.
But what happens after the three years are up? According to the PATH Malaria Vaccine Initiative, which partnered with GSK to develop the vaccine, a “considerable” amount of work is being done that could, one day, lead to implementation in different age groups (2). In other words, the new vaccine could just be the starting point.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.